New online customer portal for custom research services14 May 2018
Customers to gain a greater insight into their projects, better track project progress and improve communications.
Oxford Genetics has launched a new online customer portal designed to enable customers to better monitor project progress and track communications.
This new portal provides customers with real-time updates through 24/7 access to the status of the projects they have underway with Oxford Genetics. The system collates project information from several sources, including bespoke Enterprise Resource Planning (ERP) systems and Laboratory Information Management (LIM) systems, to produce live Gannt charts.
It also gives immediate access to all supporting documentation, such as order history, quality assurance/quality control (QA/QC) reports, and project progress reports.
Ryan Cawood, CEO of Oxford Genetics said: “The primary reason for developing the tool was that by automating data collection and dissemination many of the traditional bottlenecks of managing projects by manual methods can be eliminated.
"The launch of this portal shows our commitment to providing a more valuable and simplified online environment for our customers. We are focused on delivering both innovative technologies and exceptional service, and the deployment of this online portal helps us enhance the overall experience our customers have with us. By providing customers with visibility of their projects, they can now choose how and when to interact with our team, streamlining their user experience and allowing Oxford Genetics to be more flexible and personally responsive to each customer.
“Added to this, the growth trajectory of Oxford Genetics fed the need to improve efficiencies and streamline operations to allow the company to continue providing a high quality-service to its customers. By implementing this tool across our customer projects, we can use resources more effectively and benefit from a scalable architecture that can support hundreds of concurrent projects.”
The portal has taken around 12 months to build and was extensively tested with key customers to ensure it met the needs of all users.
Adam Marsden, Head of Informatics, Oxford Genetics said: “This new feature puts the power into the hands of our customers. No competitors in our industry have the level of laboratory automation, IT resources and back-end infrastructure to support an online portal like this."
New formulation modelling successes using ex vivo tissue
9 Oct 2018
One study uses the company's proprietary TurChub model, to evaluate the diffusion and subsequent activity of drugs in human nails.Read more
Three-way collaboration to advance gene therapy
4 Oct 2018
Partnership aims to increase the robustness and reduce costs for the manufacturing of AAV vectors.Read more
New oral treatment for metastatic melanoma receives EU authorisation
24 Sep 2018
Encorafenib in combination with binimetinib demonstrated 14.9 months median progression-free survival compared with vemurafenib monotherapy (7.3 months).Read more
Plasticell wins military contract to develop regenerative medicines for the battlefield
4 Sep 2018
Company to use its combinatorial stem cell screening platform to develop technologies for the conversion of pluripotent stem cells into platelets.Read more
New biopharmaceutical testing laboratory to open in Geneva
28 Aug 2018
SGS's expansion will enable the service provider to offer a full ICH Q6B physico-chemical characterization of biological products.Read more
Exosome isolation manufacturing and characterization
13 Aug 2018
New service to reliably and reproducibly isolate exosomes from almost any biofluid.Read more
Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines
8 Aug 2018
Company moves away from manual processing in favour of automated, scalable platforms.Read more
A new era for migraine patients
6 Aug 2018
EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.Read more
WuXi STA and Antengene sign development and manufacturing agreement
24 Jul 2018
WuXi STA chosen for its end-to-end CMC platform for new drug development.Read more
ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project
18 Jul 2018
Parallel cell line development and analysis will allow for optimal cell line selection while compressing the development timeline.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation